Genelux (GNLX) Share-based Compensation (2022 - 2026)
Genelux (GNLX) posted quarterly Share-based Compensation of $1.4 million for Q1 2026, down 2.04% year-over-year from $1.4 million in Q1 2025, and down 9.19% quarter-over-quarter from $1.5 million in Q4 2025.
Genelux (GNLX) Share-based Compensation (2022 - 2026) Analysis & Trends
Genelux's Share-based Compensation history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 2.04% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $5.8 million (down 1.08% YoY), while the FY2025 annual figure was $5.9 million, up 2.32% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.4 million, down from $1.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $21.4 million in Q3 2023, with the low at -$42000.0 in Q4 2023.
- The 5-year median for Share-based Compensation is $1.4 million (2026), against an average of $2.4 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 197.67% in 2023, then surged 3504.76% in 2024.
- Genelux's Share-based Compensation stood at $43000.0 in 2022, then plunged by 197.67% to -$42000.0 in 2023, then soared by 3504.76% to $1.4 million in 2024, then gained by 7.34% to $1.5 million in 2025, then dropped by 9.19% to $1.4 million in 2026.
- Business Quant data shows GNLX's Share-based Compensation at $1.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | 1.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.62 Mn |
| Sep 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | -42,000.00 |
| Dec 31, 2023 | -42,000.00 |